These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38228971)

  • 1. The spatial extent of tauopathy on [
    Gérard T; Colmant L; Malotaux V; Salman Y; Huyghe L; Quenon L; Dricot L; Ivanoiu A; Lhommel R; Hanseeuw B
    Eur J Nucl Med Mol Imaging; 2024 May; 51(6):1662-1674. PubMed ID: 38228971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal 18F-MK-6240 tau tangles accumulation follows Braak stages.
    Pascoal TA; Benedet AL; Tudorascu DL; Therriault J; Mathotaarachchi S; Savard M; Lussier FZ; Tissot C; Chamoun M; Kang MS; Stevenson J; Massarweh G; Guiot MC; Soucy JP; Gauthier S; Rosa-Neto P
    Brain; 2021 Dec; 144(11):3517-3528. PubMed ID: 34515754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 18F-MK-6240 PET for early and late detection of neurofibrillary tangles.
    Pascoal TA; Therriault J; Benedet AL; Savard M; Lussier FZ; Chamoun M; Tissot C; Qureshi MNI; Kang MS; Mathotaarachchi S; Stevenson J; Hopewell R; Massarweh G; Soucy JP; Gauthier S; Rosa-Neto P
    Brain; 2020 Sep; 143(9):2818-2830. PubMed ID: 32671408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Widespread brain tau and its association with ageing, Braak stage and Alzheimer's dementia.
    Lowe VJ; Wiste HJ; Senjem ML; Weigand SD; Therneau TM; Boeve BF; Josephs KA; Fang P; Pandey MK; Murray ME; Kantarci K; Jones DT; Vemuri P; Graff-Radford J; Schwarz CG; Machulda MM; Mielke MM; Roberts RO; Knopman DS; Petersen RC; Jack CR
    Brain; 2018 Jan; 141(1):271-287. PubMed ID: 29228201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease.
    Maass A; Landau S; Baker SL; Horng A; Lockhart SN; La Joie R; Rabinovici GD; Jagust WJ;
    Neuroimage; 2017 Aug; 157():448-463. PubMed ID: 28587897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 18F-flortaucipir PET to autopsy comparisons in Alzheimer's disease and other neurodegenerative diseases.
    Soleimani-Meigooni DN; Iaccarino L; La Joie R; Baker S; Bourakova V; Boxer AL; Edwards L; Eser R; Gorno-Tempini ML; Jagust WJ; Janabi M; Kramer JH; Lesman-Segev OH; Mellinger T; Miller BL; Pham J; Rosen HJ; Spina S; Seeley WW; Strom A; Grinberg LT; Rabinovici GD
    Brain; 2020 Dec; 143(11):3477-3494. PubMed ID: 33141172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suspecting Non-Alzheimer's Pathologies and Mixed Pathologies: A Comparative Study Between Brain Metabolism and Tau Images.
    Malotaux V; Colmant L; Quenon L; Huyghe L; Gérard T; Dricot L; Ivanoiu A; Lhommel R; Hanseeuw B
    J Alzheimers Dis; 2024; 97(1):421-433. PubMed ID: 38108350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CSF tau368/total-tau ratio reflects cognitive performance and neocortical tau better compared to p-tau181 and p-tau217 in cognitively impaired individuals.
    Simrén J; Brum WS; Ashton NJ; Benedet AL; Karikari TK; Kvartsberg H; Sjons E; Lussier FZ; Chamoun M; Stevenson J; Hopewell R; Pallen V; Ye K; Pascoal TA; Zetterberg H; Rosa-Neto P; Blennow K
    Alzheimers Res Ther; 2022 Dec; 14(1):192. PubMed ID: 36544221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct Comparison of the Tau PET Tracers
    Gogola A; Minhas DS; Villemagne VL; Cohen AD; Mountz JM; Pascoal TA; Laymon CM; Mason NS; Ikonomovic MD; Mathis CA; Snitz BE; Lopez OL; Klunk WE; Lopresti BJ
    J Nucl Med; 2022 Jan; 63(1):108-116. PubMed ID: 33863821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tau PET imaging with
    Mueller A; Bullich S; Barret O; Madonia J; Berndt M; Papin C; Perrotin A; Koglin N; Kroth H; Pfeifer A; Tamagnan G; Seibyl JP; Marek K; De Santi S; Dinkelborg LM; Stephens AW
    J Nucl Med; 2020 Jun; 61(6):911-919. PubMed ID: 31712323
    [No Abstract]   [Full Text] [Related]  

  • 11. Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β-Amyloid and Tauopathy.
    Wang L; Benzinger TL; Su Y; Christensen J; Friedrichsen K; Aldea P; McConathy J; Cairns NJ; Fagan AM; Morris JC; Ances BM
    JAMA Neurol; 2016 Sep; 73(9):1070-7. PubMed ID: 27454922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In Vivo Characterization and Quantification of Neurofibrillary Tau PET Radioligand
    Betthauser TJ; Cody KA; Zammit MD; Murali D; Converse AK; Barnhart TE; Stone CK; Rowley HA; Johnson SC; Christian BT
    J Nucl Med; 2019 Jan; 60(1):93-99. PubMed ID: 29777006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intermediate flortaucipir uptake is associated with Aβ-PET and CSF tau in asymptomatic adults.
    McSweeney M; Pichet Binette A; Meyer PF; Gonneaud J; Bedetti C; Ozlen H; Labonté A; Rosa-Neto P; Breitner J; Poirier J; Villeneuve S;
    Neurology; 2020 Mar; 94(11):e1190-e1200. PubMed ID: 32015176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of pharmacokinetic modeling strategies for in-vivo quantification of tau with the radiotracer [
    Guehl NJ; Wooten DW; Yokell DL; Moon SH; Dhaynaut M; Katz S; Moody KA; Gharagouzloo C; Kas A; Johnson KA; El Fakhri G; Normandin MD
    Eur J Nucl Med Mol Imaging; 2019 Sep; 46(10):2099-2111. PubMed ID: 31332496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-sectional associations between [
    Teng E; Ward M; Manser PT; Sanabria-Bohorquez S; Ray RD; Wildsmith KR; Baker S; Kerchner GA; Weimer RM
    Neurobiol Aging; 2019 Sep; 81():138-145. PubMed ID: 31280117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
    Leuzy A; Smith R; Cullen NC; Strandberg O; Vogel JW; Binette AP; Borroni E; Janelidze S; Ohlsson T; Jögi J; Ossenkoppele R; Palmqvist S; Mattsson-Carlgren N; Klein G; Stomrud E; Hansson O
    JAMA Neurol; 2022 Feb; 79(2):149-158. PubMed ID: 34928318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amyloid and tau imaging biomarkers explain cognitive decline from late middle-age.
    Betthauser TJ; Koscik RL; Jonaitis EM; Allison SL; Cody KA; Erickson CM; Rowley HA; Stone CK; Mueller KD; Clark LR; Carlsson CM; Chin NA; Asthana S; Christian BT; Johnson SC
    Brain; 2020 Jan; 143(1):320-335. PubMed ID: 31886494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tau PET in autosomal dominant Alzheimer's disease: relationship with cognition, dementia and other biomarkers.
    Gordon BA; Blazey TM; Christensen J; Dincer A; Flores S; Keefe S; Chen C; Su Y; McDade EM; Wang G; Li Y; Hassenstab J; Aschenbrenner A; Hornbeck R; Jack CR; Ances BM; Berman SB; Brosch JR; Galasko D; Gauthier S; Lah JJ; Masellis M; van Dyck CH; Mintun MA; Klein G; Ristic S; Cairns NJ; Marcus DS; Xiong C; Holtzman DM; Raichle ME; Morris JC; Bateman RJ; Benzinger TLS
    Brain; 2019 Apr; 142(4):1063-1076. PubMed ID: 30753379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Region-Specific Association of Subjective Cognitive Decline With Tauopathy Independent of Global β-Amyloid Burden.
    Buckley RF; Hanseeuw B; Schultz AP; Vannini P; Aghjayan SL; Properzi MJ; Jackson JD; Mormino EC; Rentz DM; Sperling RA; Johnson KA; Amariglio RE
    JAMA Neurol; 2017 Dec; 74(12):1455-1463. PubMed ID: 28973551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tracer Kinetic Analysis of (S)-¹⁸F-THK5117 as a PET Tracer for Assessing Tau Pathology.
    Jonasson M; Wall A; Chiotis K; Saint-Aubert L; Wilking H; Sprycha M; Borg B; Thibblin A; Eriksson J; Sörensen J; Antoni G; Nordberg A; Lubberink M
    J Nucl Med; 2016 Apr; 57(4):574-81. PubMed ID: 26795290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.